- Home
- RPRX vs REG Comparison
RPRX vs REG Comparison
Compare RPRX & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- REG
- Stock Information
- Founded
- RPRX 1996
- REG 1963
- Country
- RPRX United States
- REG United States
- Employees
- RPRX N/A
- REG N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- REG Real Estate Investment Trusts
- Sector
- RPRX Health Care
- REG Real Estate
- Exchange
- RPRX Nasdaq
- REG Nasdaq
- Market Cap
- RPRX 15.6B
- REG 13.1B
- IPO Year
- RPRX 2020
- REG 1993
- Fundamental
- Price
- RPRX $35.15
- REG $70.97
- Analyst Decision
- RPRX Strong Buy
- REG Buy
- Analyst Count
- RPRX 3
- REG 13
- Target Price
- RPRX $45.33
- REG $78.46
- AVG Volume (30 Days)
- RPRX 3.9M
- REG 1.1M
- Earning Date
- RPRX 11-05-2025
- REG 10-27-2025
- Dividend Yield
- RPRX 2.50%
- REG 3.95%
- EPS Growth
- RPRX 54.86
- REG 2.52
- EPS
- RPRX 2.32
- REG 2.14
- Revenue
- RPRX $2,305,243,000.00
- REG $1,547,928,000.00
- Revenue This Year
- RPRX $33.77
- REG $1.98
- Revenue Next Year
- RPRX $4.62
- REG $4.11
- P/E Ratio
- RPRX $15.12
- REG $33.36
- Revenue Growth
- RPRX 3.02
- REG 6.08
- 52 Week Low
- RPRX $24.05
- REG $63.44
- 52 Week High
- RPRX $38.00
- REG $78.18
- Technical
- Relative Strength Index (RSI)
- RPRX 40.78
- REG 42.43
- Support Level
- RPRX $35.97
- REG $71.84
- Resistance Level
- RPRX $36.94
- REG $72.46
- Average True Range (ATR)
- RPRX 0.85
- REG 0.95
- MACD
- RPRX -0.06
- REG -0.19
- Stochastic Oscillator
- RPRX 33.46
- REG 9.87
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 482 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.